The Burden of adolescent depression and the impact of COVID-19 across 204 countries and regions from 1990 to 2021: results from the 2021 global burden of disease study
- PMID: 39955319
- PMCID: PMC11830012
- DOI: 10.1038/s41598-024-84843-w
The Burden of adolescent depression and the impact of COVID-19 across 204 countries and regions from 1990 to 2021: results from the 2021 global burden of disease study
Abstract
This study aims to analyze the trends in the burden of depression among adolescents aged 10 to 24 years globally from 1990 to 2021, with a focus on the impact of COVID-19 on adolescent depression and health inequalities. Using data from the 2021 Global Burden of Disease Study, we examined age-standardized prevalence, incidence, and disability-adjusted life years (DALYs) for depression among adolescents aged 10-24 years. Estimated annual percentage change (EAPC) was used to assess temporal trends. Age-period-cohort (APC) analysis estimated age, period, and cohort effects. Bayesian APC (BAPC) analysis projected future trends. Decomposition analysis further explored drivers of changes in depression burden. Slope Index of Inequality (SII) and Concentration Index (CI) were calculated to assess health inequalities across regions and countries. From 1990 to 2021, the global incidence, prevalence and DALY rates of adolescent depression remained stable. Depression incidence and prevalence increased with age, with the 20-24 age group showing the highest rates. The burden of depression was higher in females than in males. The COVID-19 pandemic significantly impacted adolescent depression, with reported prevalence, incidence, and DALY rates in 2020 and 2021 far exceeding predicted values, and the burden of depression is expected to continue rising. Health inequalities between adolescents in high- and low-income regions have widened, particularly following the pandemic. The COVID-19 pandemic significantly exacerbated the burden of depression and intensified health inequalities.
Keywords: Adolescents; Depression; Epidemiology; Global burden of Disease Study; Mental Health.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures




Similar articles
-
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17. Lancet. 2024. PMID: 38642570 Free PMC article.
-
Global, regional and national temporal trends in Parkinson's disease incidence, disability-adjusted life year rates in middle-aged and older adults: a cross-national inequality analysis and Bayesian age-period-cohort analysis based on the global burden of disease 2021.Neurol Sci. 2025 Apr;46(4):1647-1660. doi: 10.1007/s10072-024-07941-7. Epub 2024 Dec 14. Neurol Sci. 2025. PMID: 39673044
-
Global, regional, and national disability-adjusted life years and prevalence of lymphatic filariasis from 1990 to 2021: A trend and health inequality analysis based on the global burden of disease study 2021.PLoS Negl Trop Dis. 2025 Apr 29;19(4):e0013017. doi: 10.1371/journal.pntd.0013017. eCollection 2025 Apr. PLoS Negl Trop Dis. 2025. PMID: 40300002 Free PMC article.
-
Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.Lancet Respir Med. 2025 May;13(5):425-446. doi: 10.1016/S2213-2600(25)00003-7. Epub 2025 Mar 24. Lancet Respir Med. 2025. PMID: 40147466
-
Analysis of global prevalence, DALY and trends of inflammatory bowel disease and their correlations with sociodemographic index: Data from 1990 to 2019.Autoimmun Rev. 2024 Nov;23(11):103655. doi: 10.1016/j.autrev.2024.103655. Epub 2024 Oct 2. Autoimmun Rev. 2024. PMID: 39366514 Review.
Cited by
-
Agomelatine Alleviates Depressive-like Behaviors by Suppressing Hippocampal Oxidative Stress in the Chronic Social Defeat Stress Model.Antioxidants (Basel). 2025 Mar 28;14(4):410. doi: 10.3390/antiox14040410. Antioxidants (Basel). 2025. PMID: 40298761 Free PMC article.
-
Advances in the prevalence and treatment of depression for adolescents: a review.Front Pharmacol. 2025 May 6;16:1574574. doi: 10.3389/fphar.2025.1574574. eCollection 2025. Front Pharmacol. 2025. PMID: 40406494 Free PMC article. Review.
References
-
- Greenfield, B. L., Venner, K. L., Kelly, J. F., Slaymaker, V. & Bryan, A. D. The impact of depression on abstinence self-efficacy and substance use outcomes among emerging adults in residential treatment. Psychol. Addict. Behaviors: J. Soc. Psychologists Addict. Behav.26, 246–254. 10.1037/a0026917 (2012). - PMC - PubMed
-
- Kim, J. & Lee, J. Prospective study on the reciprocal relationship between intimate partner violence and depression among women in Korea. Soc. Sci. Med.99, 42–48. 10.1016/j.socscimed.2013.10.014 (2013). - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical